目的 探討瑞舒伐他汀和阿托伐他汀對冠心病患者的臨床療效及對血清中白介素-35（IL-35）、核因子-κB （NF-κB）水平的影響。方法 選取100例冠心病患者，根據(jù)使用藥物不同分為兩組，對照組（49例）口服阿托伐他汀鈣片，觀察組（51例）口服瑞舒伐他汀鈣片，通過治療前后的血脂水平，IL-35、NF-κB水平及治療期間不良反應(yīng)發(fā)生情況，評價不同他汀類藥物對冠心病患者的臨床療效差異。結(jié)果 治療前，兩組三酰甘油（TG）、總膽固醇（TC）、低密度脂蛋白膽固醇（LDL-C）、高密度脂蛋白膽固醇（HDL-C）水平相比，無統(tǒng)計學(xué)差異；治療后，兩組TG、TC、LDL-C水平均降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且觀察組LDL-C水平低于對照組，差異有統(tǒng)計學(xué)意義（P<0.05），TG、TC水平比較無統(tǒng)計學(xué)差異；兩組HDL-C水平均升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05），但組間比較無統(tǒng)計學(xué)差異。治療前，兩組血清IL-35、NF-κB水平相比，無統(tǒng)計學(xué)差異；治療后，兩組患者血清IL-35水平均升高，血清NF-κB水平均降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且觀察組IL-35水平明顯高于對照組，NF-κB水平明顯低于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。治療期間，兩組不良反應(yīng)率無統(tǒng)計學(xué)差異。結(jié)論 瑞舒伐他汀和阿托伐他汀對冠心病均具有較好的調(diào)脂作用，瑞舒伐他汀對LDL-C的降低效果更明顯，此外，瑞舒伐他汀能更好地控制體內(nèi)炎癥反應(yīng)，不良反應(yīng)少，是臨床治療冠心病的理想藥物。

Objective To compare the clinical efficacy and serum levels of IL-35 and NF-κB of rosuvastatin and atorvastatin in patients with coronary heart disease. Methods 100 patients with coronary heart disease were selected, they were divided into two groups according to different statins. The control group (49 cases) was given atorvastatin calcium tablets. The observation group (51 cases) was given rosuvastatin calcium tablets. The effect of different statins in treatment of coronary heart disease was evaluated by lipid levels, IL-35, NF-κB level before and after treatment, adverse reaction during treatment. Results Before treatment, The TG, TC, LDL-C, HDL-C levels of two groups had no significant difference. After treatment, the TG, TC, LDL-C levels of two groups were decreased, and the LDL-C level in the observation group was lower than that of the control group (P<0.05). The TG, TC level had no significant differences between two groups. After treatment, the HDL-C levels were increased in two groups. There were no significant differences between groups. Before treatment, there were no statistical significance on serum IL-35, NF-κB level. After treatment, the IL-35 level was increased and NF-κB was decreased in two groups (P<0.05). And the IL-35 level was higher than that of the control group, the NF-κB level was lower than that the control group (P<0.05). During treatment, there was no statistical significance on adverse reaction between two groups. Conclusion Rosuvastatin and Atorvastatin have good lipid-lowering effect on coronary heart disease. Rosuvastatin can reduce the LDL-C obviously. These drugs can control the inflammation reaction, with less adverse reaction. It is the ideal lipid-lowering drug in clinical treatment of coronary heart disease.